Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers

Next Previous
Trial Profile

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brenetafusp (Primary) ; Atezolizumab; Bevacizumab; Docetaxel; Doxorubicin; Gemcitabine; Osimertinib; Paclitaxel; Pembrolizumab; Tebentafusp
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Large cell carcinoma; Malignant melanoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Ovarian cancer; Pelvic cancer; Peritoneal cancer; Skin cancer; Small cell lung cancer; Solid tumours; Synovial sarcoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer; Uterine cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PRAME-A02
  • Sponsors Immunocore

Most Recent Events

  • 06 Nov 2024 According to an Immunocore media release, the Company continues signal detection for brenetafusp in metastatic non-small-cell lung cancer cohorts, including in combination with docetaxel and with osimertinib in earlier-line NSCLC. As a result, the Company will not release initial data in the fourth quarter of 2024.
  • 26 Oct 2024 Planned End Date changed from 1 Jun 2026 to 1 Aug 2026.
  • 26 Oct 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Feb 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top